Mechanistic insights into the safety of daridorexant in older adults: From postural stability to next-day function

Bonnet MH Arand DL (2010) Hyperarousal and insomnia: State of the science. Sleep Medicine Reviews 14: 9–15.

Boof M-L Dingemanse J Lederer K , et al. (2021) Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44: zsaa275.

Deng Q Chen H (2025) Trends in benzodiazepine and Z-drug prescriptions in Eastern China (2015–2021). Alpha Psychiatry 26: 38792.

Drake CL Cuamatzi-Castelan AS Kalmbach DA , et al. (2019) Arousability of insomnia patients is not impacted by the orexin antagonist suvorexant (10 mg and 20 mg). Sleep 42: A151–A152.

Dressle RJ Riemann D (2023) Hyperarousal in insomnia disorder: Current evidence and potential mechanisms. Journal of Sleep Research 32: e13928.

Fietze I Bassetti CLA Mayleben DW , et al. (2022) Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: A secondary analysis of a randomised placebo-controlled trial. Drugs & Aging 39: 795–810.

Garbarino S Bragazzi NL (2024) Revolutionizing sleep health: The emergence and impact of personalized sleep medicine. Journal of Personalized Medicine 14: 598.

Kishi T Ikuta T Citrome L , et al. (2025) Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: A systematic review and network meta-analysis. Translational Psychiatry 15: 211.

Knechel NA Chang P (2022) The relationships between sleep disturbance and falls: A systematic review. Journal of Sleep Research 31: e13580.

Kunz D Dauvilliers Y Benes H , et al. (2023) Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 37: 93–106.

León-Barriera R Chaplin MM Kaur J , et al. (2025) Insomnia in older adults: A review of treatment options. Cleveland Clinic Journal of Medicine 92: 43–50.

Magliocca M Koopmans I Vaillant C , et al. (2025) Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function. Journal of Psychopharmacology 39: 223–232.

Mignot E Mayleben D Fietze I , et al. (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology 21: 125–139.

Muehlan C Brooks S Vaillant C , et al. (2022) Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator. Clinical Pharmacology & Therapeutics 111: 1334–1342.

Murphy P Kumar D Zammit G , et al. (2020) Safety of lemborexant versus placebo and zolpidem: Effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. Journal of Clinical Sleep Medicine 16: 765–773.

Qi L Liu J (2026) Advancing digital inclusion and cognitive monitoring for older adults. Asian Journal of Psychiatry 117: 104839.

Seol J Fujii Y Park I , et al. (2019) Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical/cognitive functions after forced awakening. Proceedings of the National Academy of Sciences 116: 24353–24358.

Uchiyama M Mishima K Yagi T , et al. (2025) Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies. Journal of Sleep Research 34: e14302.

US Food and Drug Administration (2022) QUVIVIQ (Daridorexant) Tablets, for Oral Use (US Prescribing Information). US Food and Drug Administration.

Wang Q Zhou Q Du Z , et al. (2024) Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports. Journal of Affective Disorders 362: 552–559.

Watson NF Fernandez CR (2021) Artificial intelligence and sleep: Advancing sleep medicine. Sleep Medicine Reviews 59: 101512.